8-K
filed May 8, 2026, 7:59 PM ET
ticker ATOS
CIK 0001488039
earnings
confidence high
sentiment positive
materiality 0.65
Operating expenses $9.9M, up 34% YoY; FDA grants RPD for (Z)-endoxifen in DMD and McCune-Albright
ATOSSA THERAPEUTICS, INC.
2026-Q1 EPS reported
-$1.11
- Total operating expenses $9.9M in Q1 2026, up from $7.4M in Q1 2025, driven by higher legal fees for patent litigation (subsequently settled) and R&D costs.
- R&D expenses $4.8M (+15% YoY) on increased clinical trial costs for (Z)-endoxifen; G&A $5.1M (+56%) due to $1.8M in patent litigation legal fees.
- FDA granted Orphan Drug Designation (Jan 2026) and Rare Pediatric Disease designation for (Z)-endoxifen in Duchenne Muscular Dystrophy.
- FDA granted Rare Pediatric Disease designation for (Z)-endoxifen in McCune-Albright Syndrome (May 2026), eligible for Priority Review Voucher (sold for $100-205M).
- Atossa strengthened leadership with two new Medical Directors: Dr. Puyana Theall (Breast Oncology) and Dr. Giwa (Rare Diseases).
Machine-readable event card
- schema_version
- secwatch.filing_event.v1
- accession
- 0001193125-26-213439
- form_type
- 8-K
- ticker
- ATOS
- cik
- 0001488039
- company_name
- ATOSSA THERAPEUTICS, INC.
- filed_at
- 2026-05-08T23:59:59+00:00
- discovered_at
- 2026-05-14T18:02:32.353685+00:00
- generated_at
- 2026-05-14T21:03:34.732484+00:00
- sec_items
- ["2.02", "9.01"]
- event_type
- earnings
- sentiment
- positive
- materiality_score
- 0.65
- calibrated_materiality_score
- 0.65
- confidence
- high
- secwatch_canonical_url
- https://secwatch.observer/filing/0001193125-26-213439
- json_url
- https://secwatch.observer/filing/0001193125-26-213439.json
- markdown_url
- https://secwatch.observer/filing/0001193125-26-213439.md
- text_url
- https://secwatch.observer/filing/0001193125-26-213439.txt
- edgar_index_url
- https://www.sec.gov/Archives/edgar/data/1488039/000119312526213439/0001193125-26-213439-index.htm
- edgar_primary_document_url
- https://www.sec.gov/Archives/edgar/data/1488039/000119312526213439/atos-20260508.htm
- generated_by_model
- deepseek-v4-flash:cloud@v2
- review_status
- machine_generated
- human_reviewed
- false
- corrected
- false
- correction_note
- null
- correction_timestamp
- null
- superseded_by
- null
Comparable filings
GMRS
GMR Solutions Q1 revenue $1.46B (+6.6% YoY), net income $106M (+180% YoY), guides FY26 rev $5.9-6.2B
GMR Solutions Inc.
June 1, 2026, 4:45 PM ET
earnings
Items 2.02, 9.01
same fact type: earnings_release
same SEC item: 2.02, 9.01
same event type: earnings
similar materiality
This filing
On May 8, 2026, Atossa Therapeutics, Inc. (the “Company”) issued a press release announcing the first quarter ended March 31, 2026 financial results and providing a Company update.
Comparable filing
today announced financial results for the first quarter ended March 31, 2026, and full year 2026 financial guidance. First Quarter 2026 Financial Highlights ● Net revenue of $1,457.6 million, up 6.6% compared to $1,367.4 million in the first quarter of 2025 ● Net income of $106.3 million, up 179.7% compared to $38.0 million in the first quarter of 2025 ● Adjusted
Filing page
SEC filing
DAVEY TREE EXPERT CO
Davey Tree Q1 net loss widens to $10.7M; revenue flat at $435.8M
DAVEY TREE EXPERT CO
June 1, 2026, 1:50 PM ET
earnings
Items 2.02, 9.01
same fact type: earnings_release
same SEC item: 2.02, 9.01
same event type: earnings
similar materiality
This filing
On May 8, 2026, Atossa Therapeutics, Inc. (the “Company”) issued a press release announcing the first quarter ended March 31, 2026 financial results and providing a Company update.
Comparable filing
Exchange Act, unless such subsequent filing specifically references this Form 8-K.
--- EX-99.1 (EX-99.1) ---
To Our Shareholders, The Company’s first quarter 2026 revenue of $435.8 million increased slightly from the record first quarter 2025 revenue by $1.0 million, or 0.2%. This growth was driven by consistent demand in the Utility segment, where revenue
Filing page
SEC filing
DXYN
Dixie Group Q1 2026 net income $1.4M vs loss of $1.6M YoY; sales down 5.7%
DIXIE GROUP INC
May 11, 2026, 7:59 PM ET
earnings
Items 2.02, 9.01
same fact type: earnings_release
same SEC item: 2.02, 9.01
same event type: earnings
similar materiality
This filing
On May 8, 2026, Atossa Therapeutics, Inc. (the “Company”) issued a press release announcing the first quarter ended March 31, 2026 financial results and providing a Company update.
Comparable filing
2026) -- The Dixie Group, Inc. (OTCQB: DXYN) today reported financial results for the quarter ended March 28, 2026. For the first quarter of 2026, the Company had net sales of $59,380,000 as compared to $62,990,000 in the same quarter of 2025. The Company had an operating income of $3,264,000 in the first quarter of 2026 compared to an operating income of $11,000
Filing page
SEC filing
SNDA
Sonida Senior Living reports Q1 net loss of $41.2M; revenue up 37% on CHP acquisition
SONIDA SENIOR LIVING, INC.
May 11, 2026, 7:59 PM ET
earnings
Items 2.02, 8.01, 9.01
same fact type: earnings_release
same SEC item: 2.02, 9.01
same event type: earnings
similar materiality
This filing
On May 8, 2026, Atossa Therapeutics, Inc. (the “Company”) issued a press release announcing the first quarter ended March 31, 2026 financial results and providing a Company update.
Comparable filing
Sonida Senior Living Announces First Quarter 2026 Results DALLAS, Texas – May 11, 2026 – Sonida Senior Living, Inc. (the “Company,” “Sonida,” “we,” “our,” or “us”) (NYSE: SNDA), a leading owner, operator and investor of senior housing communities, today announced its results for the first quarter ended March 31, 2026.
Filing page
SEC filing
URG
Ur-Energy Q1 2026: pounds captured up 41% QoQ, avg price $70.98, Shirley Basin commenced
UR-ENERGY INC
May 11, 2026, 7:59 PM ET
earnings
Items 2.02, 9.01
same fact type: earnings_release
same SEC item: 2.02, 9.01
same event type: earnings
similar materiality
This filing
On May 8, 2026, Atossa Therapeutics, Inc. (the “Company”) issued a press release announcing the first quarter ended March 31, 2026 financial results and providing a Company update.
Comparable filing
a 14% increase over Q4 2025 and a 13% increase over Q1 2025. Financial Performance ◾ Contracted Sales: We sold 55,000 produced pounds of U 3 O 8 as anticipated, generating $3.9 million in revenue, with a majority of our 2026 deliveries scheduled for the latter part of the year to complement the ramp-up and start-up schedules of Lost Creek and Shirley Basin. ◾
Filing page
SEC filing
EXPI
eXp World Holdings Q1 revenue $1.0B (+5% YoY), net loss narrows to $(5.1M), Adj. EBITDA $4.1M (+88%)
eXp World Holdings, Inc.
May 11, 2026, 7:59 PM ET
earnings
Items 2.02, 7.01, 9.01
same fact type: earnings_release
same SEC item: 2.02, 9.01
same event type: earnings
similar materiality
This filing
On May 8, 2026, Atossa Therapeutics, Inc. (the “Company”) issued a press release announcing the first quarter ended March 31, 2026 financial results and providing a Company update.
Comparable filing
the company's scale and our focus on operational efficiency across eXp World Holdings,” said Jesse Hill, Chief Financial Officer of eXp World Holdings. “We generated revenue of $1.0 billion and Adjusted EBITDA of $4.1 million, an 88% improvement that further strengthened our financial position. More recently, we executed the strategic NextHome acquisition using cash
Filing page
SEC filing
BATRA
Atlanta Braves Holdings Q1 revenue up 53% to $72M; operating loss narrows to $41M
Atlanta Braves Holdings, Inc.
May 11, 2026, 7:59 PM ET
earnings
Items 2.02, 9.01
same fact type: earnings_release
same SEC item: 2.02, 9.01
same event type: earnings
similar materiality
This filing
On May 8, 2026, Atossa Therapeutics, Inc. (the “Company”) issued a press release announcing the first quarter ended March 31, 2026 financial results and providing a Company update.
Comparable filing
Total revenue grew to $72 million in the first quarter of 2026, up 53% from the prior year period.
Filing page
SEC filing
SBH
Sally Beauty Q2 sales up 2.3%; GAAP EPS $0.43 beats year-ago $0.38; guidance range narrowed
Sally Beauty Holdings, Inc.
May 11, 2026, 7:59 PM ET
earnings
Items 2.02, 7.01, 9.01
same fact type: earnings_release
same SEC item: 2.02, 9.01
same event type: earnings
similar materiality
This filing
On May 8, 2026, Atossa Therapeutics, Inc. (the “Company”) issued a press release announcing the first quarter ended March 31, 2026 financial results and providing a Company update.
Comparable filing
Consolidated net sales of $903 million, an increase of 2.3% compared to the prior year; • Consolidated comparable sales growth of 1.3%; • Global e-commerce sales increased 13% to $108 million, representing 12% of net sales; • GAAP gross margin expansion of 70 basis points to 52.7%; • Adjusted Gross Margin expansion of 80 basis points to 52.8%; • GAAP selling, general and administrative expenses of $404 million, an increase of $14 million compared to the prior year; • Adjusted Selling, General and Administrative Expenses of $404 million, an increase of $20 million compared to the prior year; • GAAP operating earnings of $72 million and GAAP operating margin of 8.0%; • Adjusted Operating Earnings of $73 million and Adjusted Operating Margin of 8.1%; • GAAP diluted net earnings per share of $0.43, an increase of 13% compared to the prior year;
Filing page
SEC filing
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.